S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer

AIM:To investigate the feasibility and efficacy of the combination of S-1 with gemcitabine followed by oral S-1 with concurrent radiotherapy(intensity modulated radiotherapy,IMRT) and maintenance therapy with S-1 for locally advanced pancreatic cancer.METHODS:Subjects selected in the study were patients who had unresectable and locally advanced pancreatic cancer without distant metastases,adequate organ and marrow functions,an Eastern Cooperative Oncology Group performance status of 0-1 and no prior anticancer therapy. Initially the subjects received two cycles of chemotherapy,oral administration of S-1 40 mg/m2 twice daily from day 1 to day 14 of a 21-d cycle,with 30-min intravenous infusions of gemcitabine 1000 mg/m2 on day 1 and day 8. Two weeks after the completion of chemotherapy,S-1 was administered orally with concurrent IMRT. Oral S-1 was administered at a dose of 80 mg/m2 per day twice daily from day 1 to day 14 and from day 22 to day 35. Radiation was concurrently delivered at a dose of 50.4 Gy(1.8 Gy/d,5 times per week,28 fractions). One month after the completion of chemotherapy and radiotherapy,S-1 was administered orally at a dose of 80 mg/m2 per day twice daily for 14 d,followed by a 14-d rest period. This cycle was repeated as maintenance therapy,until unacceptable toxicity occurred or the disease worsened. Thirty-two patients were involved in this study. The median followup was 15.6 mo(range:8.6-32.3 mo).RESULTS:Thirty-two patients completed the scheduled course of chemotherapy,while 30 patients(93.8%) received chemoradiotherapy with two patients ceasing to continue with radiotherapy. The major toxic effects were nausea and leukopenia. There was no grade 4 toxicity or treatment-related death. According to the Response Evaluation Criteria in Solid Tumors criteria,the objective tumor response was partial response in 17(53.1%) patients,stable disease in 9(28.1%),and progressive disease in 6(18.8%). The median overall survival and median progression-free survival were 15.2 mo and 9.3 mo,respectively. The survival rates at 1 year and 2 years were 75% and 34.4%,respectively.CONCLUSION:The combination of S-1 with gemcitabine followed by oral S-1 with IMRT and maintenance therapy with S-1 alone in patients with locally advanced pancreatic cancer may be considered a well-tolerated,promising treatment regimen.

不同导电添加剂对SiO/C锂离子电池性能的影响（英文）

以SiO/C复合材料为负极的锂离子电池相比传统石墨为负极的锂离子电池具有更高能量密度,因而越来越受到开发人员的重视。而SiO/C材料由于Si的存在导致材料本体导电性差,在实体锂离子电池的制作过程中会出现内阻大和倍率性能差等问题,因此导电添加剂组成对电池性能的影响成为研究关键。本文用商业化的LiCoO_2、SiO/复合材料和电解液为主要原料,以VGCF和Super P为导电添加剂,制作了2.5 Ah容量的锂离子软包电池。SEM分析测试表明导电碳黑Super P和VGCF分散均匀,可与SiO/C颗粒形成点和线的接触,进而增强负极极片的导电性能。应用两种导电添加剂所制作的SiO/C锂离子电池的能量密度超过了600 Wh/L。相对于采用Super P导电添加剂,VGCF导电添加剂制备的锂离子电池充放电过程的膨胀更小,且倍率性能更加优异,同时低温和循环寿命均表现出更好的性能。